MCHRI Virtual Seminar Series
Monday, February 1, 2021, 12:00PM-1:00PM
Among children with B-cell progenitor acute lymphoblastic leukemia (ALL), the most common kind of childhood cancer, 15% of children will relapse after initially responding to standard therapies, and 50% of children who relapse will die, making relapsed ALL the second-leading cause of cancer-related death in children. Even with the emergence of novel immunotherapies, including chimeric antigen receptor (CAR) T-cells, at least 40% of children with ALL who initially respond to these novel therapies will still go on to relapse. As such, a critical need remains—to prevent relapse among children with ALL, thus providing a definitive cure.
In this talk, Dr. Kara Davis will discuss the use of a single-cell mass cytometry, or CyTOF, to identify cells associated with relapse from diagnostic patient samples. Using machine learning, Dr. Davis and her research team built an elastic net model to predict relapse using the measured features in the expanded B-cell populations. She will share insight into these relapse predictive cells, including differences in their response to standard leukemia therapies and differences in their cellular metabolism that may contribute to chemoresistance. Further, Dr. Davis will address the application of these tools and other single-cell approaches to study CD19-negative relapse after CD19 targeting CAR-T cell therapies.
Speaker:
Kara Davis, DO – Dr. Davis is an Assistant Professor of Pediatrics in the Division of Hematology and Oncology. Her research focuses on using single-cell analysis to organize tumor heterogeneity in pediatric cancers, especially blood cancers, as means to determine cell populations associated with clinical risks such as relapse. Clinically, Dr. Davis sees patients with leukemia and is involved with the Cancer Cellular Therapies program with experience in treating children with chimeric antigen receptor (CAR) T-cells and other immunotherapies including checkpoint inhibitors.